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Background: Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell
carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the
RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was a
powerful index for evaluating the biological response to TKI. In this study we investigated the differences in FDG
accumulation and the response to TKI as assessed by FDG PET/CT among various organs where RCC were located.
Methods: A total of 48 patients with advanced RCC treated with a TKI (25 with sunitinib and 23 with sorafenib)
were evaluated by FDG PET/CT before and at 1 month after a TKI treatment initiation. The maximum standardized
uptake value (SUVmax) of all RCC lesions were measured and analyzed.
Results: We evaluated 190 RCC lesions. The pretreatment SUVmax values (mean ± SD) were as follows: in the 49
lung metastases, 4.1 ± 3.3; in the 40 bone metastases, 5.4 ± 1.6; in the 37 lymph node metastases, 6.7 ± 2.7; in the
29 abdominal parenchymal organ metastases, 6.6 ± 2.7; in the 26 muscle or soft tissue metastases, 4.4 ± 2.6; and in
the nine primary lesions, 8.9 ± 3.9. Significant differences in the SUVmax were revealed between metastases and
primary lesions (p = 0.006) and between lung metastases and non-lung metastases (p < 0.001). The SUVmax change
ratios at 1 month after TKI treatment started were −14.2 ± 48.4% in the lung metastases, −10.4 ± 23.3% in the bone
metastases, −9.3 ± 47.4% in the lymph node metastases, −24.5 ± 41.7% in the abdominal parenchymal organ
metastases, −10.6 ± 47.4% in the muscle or soft tissue metastases, and −24.2 ± 18.3% in the primary lesions. There
was no significant difference among the organs (p = 0.531).
Conclusions: The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI
treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests
that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
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Renal cell carcinomas (RCCs) account for 3% of all ma-
lignancies in adults [1]. Approximately 30% of RCC pa-
tients have metastases at the time of diagnosis, and
20%–40% of all patients relapse or develop metastases
after radical nephrectomy with curative intent [2,3]. For
many years, classical cytokine therapies had been the
only systematic treatments available for advanced RCC,
but the response rate to the cytokine therapies was
only ~20% [4-6]. The development of novel and effective
systematic therapeutics is desirable.
The oncogenic mechanism of RCC was recently eluci-
dated, and agents have been developed that target the
relevant biological pathway that has a critical and neces-
sary role in RCC survival or progression. Tyrosine kinase
inhibitors (TKIs) such as sunitinib and sorafenib, which
target vascular endothelial growth factor (VEGF) recep-
tors, improved the prognosis of patients with advanced
RCC [7-9]. The antitumor activity of the TKIs was not
cytotoxic, as are the classical antitumor therapeutics, but
rather cytostatic, suppressing biological activity by inhi-
biting angiogenesis. Actually, some RCCs treated with
TKIs did not decrease in tumor volume but entered a
period of long-term dormancy, without an enlargement
of volume or novel metastasis. A new biological marker
evaluating the biological activities of RCC would be im-
portant if TKIs are to become the mainstay of treatment
for advanced RCC.
Based on this concept, we have been investigating the
utility of 18 F-2-fluoro-2-deoxyglucose positron emission
tomography/computed tomography (FDG PET/CT), which
is a useful non-invasive tool to evaluate glucose metabolic
status, and reported the possibility of using the standard-
ized uptake value (SUV), a semiquantitative simplified
measurement of the tissue FDG accumulation rate, as a
biomarker expressing the biological activity of RCC. We
reported previously that the maximum SUV (which was
the highest SUV in individual patients assessed by pretreat-
ment FDG PET/CT) could predict survival [10]. We then
found that the progression-free survivals of patients with
RCC showing a ≥ 20% decrease in SUVmax at 1 month
after TKI treatment started was longer than that of patients
with RCC showing a < 20% decrease in SUVmax [11].
However, it has been unclear whether pretreatment FDG
accumulation and its response to TKI were affected by the
organs where the RCC metastases were located. In the
present study we thus investigated the differences in FDG
accumulation and its response to TKI among organs where
RCC metastases were located.
Methods
Patients
We analyzed patients with advanced RCC pathologically
diagnosed by prior nephrectomy or biopsy and treatedby sunitinib or sorafenib between June 2008 and April
2013 at Yokohama City University hospital and its affili-
ated hospitals. The patients were initially assessed by
conventional imaging techniques (computed tomography
[CT], magnet resonance imaging [MRI], or bone scintig-
raphy) and diagnosed as stage IV or recurrent RCC. Pa-
tients with uncontrolled diabetes mellitus (blood glucose
level >150 mg/dL) or with other known malignancies,
and those treated with therapeutics during the 2 weeks
prior to the scan were excluded. The study protocol was
approved by the Yokohama City University Institutional
Review Board. Written informed consent was obtained
from all patients for enrollment in this study and publi-
cation of accompanying clinical records and images. The
decision for patients to undergo therapy was made be-
fore the evaluation by FDG PET/CT.
Treatment
Sunitinib was administered to each patient orally once a
day at the dose of 50 mg in 6-wk cycles consisting of 4
wks of treatment followed by 2 wks without treatment.
Oral sorafenib (800 mg) was administered daily. The
dose of sunitinib was reduced to 37.5 or 25 mg and that
of sorafenib was reduced to 600 or 400 mg according to
the patient’s pretreatment general condition or major ad-
verse events during treatment.
Imaging
FDG PET/CT was performed in all patients before and
1 month after the TKI treatment started. Patients fasted
for at least 6 h prior to an intravenous injection of 18F
FDG. PET/CT images were obtained using a PET/CT sys-
tem (Aquiduo 16; Toshiba Medical Systems, Tokyo). PET/
CT images were acquired from the top of the head to the
mid-thigh at 60 min after an intravenous injection of
2.5 MBq/kg of [18F] FDG. Mean of the time from injec-
tion to imaging was 60 min (standard deviation (SD) 6;
range 50-84). Mean of FDG dosage was 151 MBq (SD 29;
range 91-212). A low-dose non-contrasted CT scan was
acquired first and used for attenuation correction. Emis-
sion images were acquired in 3-dimensional mode for
2 min per bed position. After PET acquisition, contrast-
enhanced CT was performed with a 2-mm slice thickness,
120 kV, 400 mA, 0.5 s/tube rotation, from the top of
the head to the mid-thigh, with breath holding. A total of
100 mL of contrast medium (iopamidol) was administered
intravenously at a rate of 1.0 mL/s. The scan delay was set
at 120 s after starting the injection of contrast material.
The patients with a serum creatinine level >1.5 mg/dL
were examined without contrast material. Images were
reconstructed by attenuation-weighted ordered-subset
expectation maximization (OSEM) (four iterations, four-
teen subsets, 128 × 128 matrix, with 5-mm Gaussian
smoothing). The standardized uptake value (SUV) was





























HD*: mixed clear cell and papillary renal carcinoma in a hemodialysis patient.
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ity in the volume of interest (VOI) recorded as Bq per
mL/injected dose in Bq per total body weight (kg). The
maximum SUV (SUVmax) was recorded using the max-
imum pixel activity within the VOI. Tumor size responses
were evaluated by the Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1. The VOI was settled
to encompass the targets within areas of increased uptake
and measured on each slice by two experienced physician,
DU and KM who were blinded to clinical data. Discrepan-
cies were resolved by consensus reading. Analysis of FDG
uptake in the primary tumor was made with reference to
contrast-enhanced CT images to differentiate tumor from
physiologic parenchymal and urinary tract.
Statistical analysis
The Kruskal-Wallis test and the Mann-Whitney U-test
were used to assess the differences in pretreatment SUV-
max, post-treatment SUVmax, SUVmax change ratio,
and the diameter change ratio among organs where
RCC metastases were located. In the assessment of the
SUVmax change ratio, the RCC metastases which pre-
treatment FDG accumulations were not detected were
excluded. In the assessment of diameter change ratio,
the RCC metastases which diameter could not be mea-
sured were excluded. All statistical analyses were carried
out with SPSS software (SPSS, Chicago, IL). Significance
was assigned at p < 0.05.
Results
Patient characteristics and intervention
A total of 48 patients treated with TKIs (25 with suniti-
nib and 23 with sorafenib) were analyzed retrospectively.
The clinical characteristics of the 48 patients are detailed
in Table 1. There were 40 men and 8 women. The me-
dian age was 66 years (range 32 to 80). Of the 48 pa-
tients, 41 had clear cell carcinoma, five had papillary
carcinoma, one had mixed clear cell and papillary renal
carcinoma (a hemodialysis patient), and one had clear
cell carcinoma mixed with a sarcomatoid component.
There were 21 patients with recurrent diseases and 27
with stage IV disease.
According to the Memorial Sloan-Kettering Cancer
Center (MSKCC) classification [12], 17 patients were
classified as favorable risk, 24 as intermediate risk, and
7 as poor risk. Thirty-eight patients had undergone
nephrectomy. Thirty patients had had no previous sys-
tematic therapies, and 18 patients had previous system-
atic therapies (one with sunitinib, one with sorafenib,
two with sorafenib and interferon-alpha, 10 with inter-
feron alpha, and 2 with interferon alpha and interleukin-2,
2 with chemotherapy). These treatments ended more
than 2 wks prior to the pretreatment evaluation by FDG
PET/CT.In the 48 patients, we analyzed 190 RCC lesions diag-
nosed as RCC tumors by conventional imaging tech-
niques. The numbers of RCC lesions in individual patients
ranged from one to 10 (median three). There were 49
lung metastases (25.8%), 40 bone metastases (21.0%),
37 lymph node metastases (19.5%), 29 abdominal organ
metastases including liver, adrenal gland, pancreas, spleen,
contralateral kidney, uterus, and vagina (15.3%), 26 muscle
or soft tissue metastases (13.7%), and nine renal primary
sites (4.7%).
The assessment by FDG PET/CT
We first analyzed the SUVmax values obtained by FDG
PET/CT before treatment. The mean of interval between
The SUVmax of all lesions was 5.5 ± 3.0 (mean ± SD).
When the differences among organs were examined, we
found that the pretreatment SUVmax values were: lung
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node metastases 6.7 ± 2.7, abdominal organ metastases
6.6 ± 2.7, muscle or soft tissue metastases 4.4 ± 2.6,
and primary sites 8.9 ± 3.9 with a significant difference
(p < 0.001, Kruskal-Wallis test) (Figure 1). The mean of
pretreatment SUVmax in all metastases was 5.3 ± 2.9
and there was statistical difference in SUVmax between
renal origin and metastases (p = 0.006, Mann-Whitney
U-test). When we analyzed the differences among metas-
tases, it was revealed that the lung metastases demon-
strated significantly lower SUVmax values compared
to the non-lung metastases (p < 0.001, Mann-Whitney
U-test).
We next analyzed the SUVmax assessed by FDG PET/
CT performed 1 month after the TKI treatment initi-
ation (day 30 ± 6; range 14 to 47). The post-treatment
SUVmax of all 190 lesions was 4.6 ± 2.9 (mean ± SD).
The post-treatment SUVmax values were: lung metasta-
ses 3.5 ± 3.0 , bone metastases 4.9 ± 2.2, lymph node me-
tastases 5.6 ± 3.1, abdominal organ metastases 4.6 ± 2.8,
muscle or soft tissue metastases 3.6 ± 2.5, and primary
sites 6.6 ± 3.0, with a significant difference (p = 0.001,
Kruskal-Wallis test) (Figure 1). The mean of post-
treatment SUVmax in all metastases was 4.5 ± 2.8, and
there was a significant difference in SUVmax between
primary sites and metastases (p = 0.034, Mann-Whitney
U-test). When the differences among metastasis loca-
tions were analyzed, the lung metastases demonstrated
significantly lower SUVmax values compared to the
non-lung metastases (p = 0.014, Mann-Whitney U-test).
The SUVmax change ratio of all 190 lesions was −14.1 ±
41.1% (mean ± SD). When we analyzed the differences










Figure 1 Pretreatment and post-treatment SUVmax values of the RCCof the lung metastases was −14.2 ± 48.4%; that of bone me-
tastases was −10.4 ± 23.3%, lymph node metastases −9.3 ±
47.4%, abdominal organ metastases −24.5 ± 41.7%, muscle
or soft tissue metastases −10.6 ± 47.4%, and primary
sites −24.2 ± 18.3%. There was no significant difference
among all organs at which RCC metastases were lo-
cated (p = 0.531, Kruskal-Wallis test) (Figure 2).
Lastly, we investigated the change ratio of tumor
diameter between before and after the start of TKI treat-
ment. The ratio of all lesions was −5.0 ± 25.5% (mean ±
SD). The diameter change ratio of the lung metastases
was −9.2 ± 27.8%, that of the bone metastases 4.2 ±
15.4%, lymph node metastases −5.4 ± 36.4%, abdominal
organ metastases −2.3 ± 21.2%, muscle or soft tissue me-
tastases −11.3 ± 18.1%, and primary sites was −5.8 ±
7.2%. There was a significant difference among metasta-
sis sites (p = 0.001, Kruskal-Wallis test) (Figure 3). There
was a significant difference in the change ratio of tumor
diameter between the bone metastases and non-bone
metastases (p < 0.001, Mann-Whitney U-test).
Figure 4 shows the FDG PET/CT features in the pre-
treatment state and post-treatment state of the lung
metastases, bone metastases, lymph node metastases,
abdominal organ metastases, muscle metastases, and
primary tumors.
Discussion
We and some other investigators have found that FDG
PET/CT is a powerful tool to assess the biological status
of RCCs, and we suggested the potency of FDG PET/CT
as an imaging biomarker for advanced RCC [10,11,13-16].
One of the uses of an imaging biomarker is to evaluate




Figure 2 SUVmax change ratio after TKI treatment of the RCC patients.
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showed heterogeneity, for example between metastases
and the primary lesion in an individual patient [17]. Their
findings suggested that the biological evaluation of indi-
vidual metastases of RCC in a single patient was im-
portant, but at the same time their report raised many
clinical questions. One of the questions was whether the
biological status of an RCC and its response to treatment
are influenced by the organ at which the RCC metastasis
is located. Here we investigated the differences among or-
gans where RCC metastases were located using the assess-
ments by FDG PET/CT.Figure 3 Diameter change ratio after TKI treatment of the
RCC patients.We first focused on the differences in pretreatment FDG
accumulation among the organ where RCC metastases
were located. The primary origin showed higher pre-
treatment FDG accumulation compared to the metasta-
ses. Additionally, the lung metastases showed lower
accumulation compared to non-lung metastases when
the difference in FDG accumulation among only metas-
tases was examined, although there was not statistical
difference in the diameter between the lung metastases
and non-lung metastases (data not shown). The present
results support our hypothesis that the FDG accumula-
tion expressed biological activity of RCC and RCCs
showing high FDG accumulation predict a short survival
time. Because, there are several clinical reports that
the prognosis of RCC patients with primary tumors was
poor compared with that of patients who had undergone
a nephrectomy [18-20]. Additionally, lung metastases
showed the better response to various therapies than non-
lung metastasis and RCC patients with lung metastasis
only show longer survival than other RCC patients
[21-24]. In our study, there were only 2 patients with only
lung metastasis. The difference of prognosis cannot be an-
alyzed in such small sized study. The further study target-
ing large number of patients is necessary.
Next, we focused on the change of FDG accumulation
at 1 month after TKI treatment started, and we found
that the change ratio of FDG accumulation was not sig-
nificantly different among the organs where RCC metas-
tases were located. However, the change ratio of SUVmax
in the 190 lesions evaluated in this study showed a wide
range (median −16%, range −100 to 137). An interesting
Figure 4 FDG PET/CT features in the pretreatment state and post-treatment state. CT imaging (a), PET imaging (b) and fused imaging
(c) before treatment and CT imaging (d), PET imaging (e) and fused imaging (f) at1 month after TKI treatment initiation. A: A 55-year-old female
with lung metastasis. She was treated with sorafenib. The SUVmax showed a 25.6% decrease (from 4.3 to 3.2) and the tumor dia. showed a 13.6%
decrease. B: A 66-year-old male with lumbar vertebrae metastasis. He was treated with sunitinib. The SUVmax showed a 27.5% decrease (from 8.0
to 5.8) and the tumor dia. showed a 3.9% decrease. C: A 76-year-old male with mediastinal lymph node metastasis. He was treated with sorafenib.
The SUVmax showed a 13.2% decrease (5.3 to 4.6) and the dia. showed a 10.0% decrease. D: A 64-year-old male with adrenal gland metastasis.
He was treated with sunitinib. The SUVmax showed a 25.0% decrease (8.8 to 6.6) and the dia. a 8.5% decrease. E: A 67-year-old female with rectus
abdominis muscle metastasis. She was treated with sorafenib. The SUVmax showed a 26.5% decrease (3.4 to 2.5) and the dia. a 16.0% decrease.
F: A 71-year-old male with primary tumor in the left kidney. He was treated with sunitinib. The SUVmax showed a 21.4% decrease (8.4 to 6.6) and
the dia. did not change.
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FDG accumulation of the bone metastases was not sig-
nificantly different from that of the none-bone metasta-
ses, although the sizes of the bone metastases did not
reduce like that of the non-bone metastases did, as shown
in Figures 2 and 3. Actually, the patient whose case is
shown in Figure 4B, with bone metastasis showing a 28%
decrease in the SUVmax after sunitinib treatment started,
is alive with disease on the last observation, 40 months
after the treatment started. These results indicate that the
delivery and effect of TKIs are not influenced by the
organ location of RCC metastasis, and they suggest that
TKIs could be applied for patients with advanced RCC re-
gardless of the metastatic site.To our knowledge, this is the first report to analyze
the differences in FDG accumulation of RCC among me-
tastases locations. However, the number of patients was
limited. A further study with a larger number of patients
is necessary to test these results.Conclusion
The decrease ratio of FDG accumulation of RCC lesions
evaluated by FDG PET/CT at 1 month after TKI treat-
ment initiation was not influenced by the organs where
the RCC metastasis was located. This result suggests
that TKIs can be used to treat patients with advanced
RCC regardless of the metastatic site.
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